HC Wainwright Analysts Lower Earnings Estimates for TRDA

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Entrada Therapeutics in a research note issued on Monday, August 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.18) per share for the quarter, down from their prior forecast of ($1.17). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.07) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($3.13) EPS.

A number of other equities research analysts also recently weighed in on TRDA. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Finally, Roth Capital set a $10.00 target price on Entrada Therapeutics in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Entrada Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $17.50.

Entrada Therapeutics Stock Up 1.3%

Shares of Entrada Therapeutics stock opened at $7.04 on Wednesday. The stock has a market capitalization of $274.14 million, a price-to-earnings ratio of -1.78 and a beta of -0.26. Entrada Therapeutics has a twelve month low of $5.02 and a twelve month high of $16.45. The company has a 50-day simple moving average of $6.87 and a two-hundred day simple moving average of $9.65.

Entrada Therapeutics (NASDAQ:TRDA) last posted its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Entrada Therapeutics during the second quarter worth $19,013,000. Millennium Management LLC boosted its holdings in shares of Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after acquiring an additional 666,287 shares in the last quarter. Citadel Advisors LLC grew its position in Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after acquiring an additional 235,384 shares during the last quarter. Baker BROS. Advisors LP grew its position in Entrada Therapeutics by 4.3% during the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in Entrada Therapeutics by 115.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after purchasing an additional 154,143 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Ventures V. L.P. 5Am sold 52,317 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $6.85, for a total value of $358,371.45. Following the sale, the insider directly owned 2,783,781 shares of the company’s stock, valued at $19,068,899.85. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bernhardt G. Zeiher bought 5,000 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $5.86 per share, with a total value of $29,300.00. Following the purchase, the director owned 5,000 shares of the company’s stock, valued at approximately $29,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 451,014 shares of company stock worth $3,124,822 over the last three months. Insiders own 9.49% of the company’s stock.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.